Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
Keywords: اینترفرون ها; Direct-acting Antiviral; DAA; Short-duration; Pangenotypic; ALT; alanine aminotransferase; CI; confidence interval; DAA; direct-acting antiviral; G/P; glecaprevir/pibrentasvir; HCV; hepatitis C virus; IFN; interferon; ITT; intention-to-treat; LLOQ; lower